Axim Biotech Files Patent Application With USPTO For Cannabis Gum For Migraines

Axim Biotechnologies Inc. (OTCMKTS:AXIM) has filed a patent application for chewing gum with the United States Patent and Trademark Office (USPTO) on May 8, 2019. The patent comprises parthenolide also called the feverfew extract and cannabinoids.

Story continues below

The combination of these two is apparently effective in treating the symptoms of migraines.

AXIM formulation to treat migraine symptoms

The biotech company plans to develop a chewing gum that will provide relief from the symptoms of migraines such as pain, headache, light sensitivity, and nausea. According to the CEO of AXIM Biotech, John W. Huemoeller II, “As AXIM moves forward with its plan to build out its product line and increase revenue for the funding of clinical trials, we are proud to announce this patent application for a novel chewing gum product that aims to treat symptoms associated with such a common ailment as a migraine.”

Huemoeller II further added that some studies indicate that migraines affect around 38 million people in the United States. The aim of AXIM is to offer a natural solution for those seeking such an easy-to-take option currently unavailable in the market.

Cannabis-Related Inventions On Rise In The US

Apart from AXIM, there are many more US companies that are showing great interest in inventions and developing products comprising cannabis. The change in the overall approach towards marijuana is because of the shift in its status from an illegal controlled substance to a medicinal product developed according to regulations.

After legalization, the recreational marijuana market of today is experiencing a lot of momentum and upheaval and holds promise to grow into an incredibly valuable asset in coming years.  The shift started very early in Canada as the country 100% legalized both the medicinal and recreational use of marijuana in October 2018.

However, in the United States, marijuana is still a Schedule I drug that comes under the Controlled Substances Act. Use of medicinal marijuana is legal in 33 states in the United States. 10 states including Washington D.C. legalized the recreational use of marijuana recently. These slow moves are looking promising to inventors who are filing patent applications on the basis of their cannabis-related inventions with the USPTO.

An ad to help with our costs